摘要:
Compounds of formula (I): or pharmaceutically acceptable salts or solvates thereof, and their use as pharmaceuticals, particularly as p38 kinase inhibitors.
摘要:
Compounds of formula (I): or pharmaceutically acceptable salts or solvates thereof, and their use as pharmaceuticals, particularly as p38 kinase inhibitors.
摘要:
Compounds of formula (I) are inhibitors of p38 kinase and are useful in the treatment of conditions or disease states mediated by p38 kinase activity or mediated by cytokines produced by the activity of p38.
摘要:
Compounds of formula (I): or pharmaceutically acceptable sats or solvates thereof, and their use as pharmaceuticals, particularly as p38 kinase inhibitors.
摘要:
Compounds of formula (I): or pharmaceutically acceptable salts or solvates thereof, and their use as pharmaceuticals, particularly as p38 kinase inhibitors.
摘要:
Compounds of formula (I): or pharmaceutically acceptable salts or solvates thereof, and their use as pharmaceuticals, particularly as p38 kinase inhibitors.
摘要:
Compounds of formula (I): wherein A is a 5-membered heteroaryl ring are inhibitors of p38 kinase and are useful in the treatment of conditions or disease states mediated by p38 kinase activity or mediated by cytokines produced by the activity of p38, such as rheumatoid arthritis.
摘要:
Compounds of formula (I) wherein when m is 0 to 4 R1 is selected from C1-6alkyl, C3-7cycloalkyl, C2-6alkenyl, —SO2NR4R5, —CONR4R5 and —COOR4; and when m is 2 to 4 R1 is additionally selected from C1-6alkoxy, hydroxy, NR4R5, —NR4SO2R5, —NR4SOR5, —NR4COR5, and —NR4CONR4R5; R2 is selected from hydrogen, C1-6alkyl and —(CH2)n—C3-7cycloalkyl; R3 is the group R6 is selected from hydrogen and C1-4alkyl; U is selected from methyl and halogen; X and Y are each selected independently from hydrogen, methyl and halogen; m is selected from 0, 1, 2, 3 and 4 wherein each carbon atom of the resulting carbon chain may be optionally substituted with one or two groups selected independently from C1-6alkyl; n is selected from 0, 1, 2 and 3; r is selected from 0, 1 and 2; or pharmaceutically acceptable salts or solvates thereof, and their use as pharmaceuticals, particularly as p38 kinase inhibitors.
摘要翻译:式(I)的化合物,其中当m为0至4时R 1选自C 1-6烷基,C 3-7环烷基,C 2-6烯基,-SO 2 NR 4 R 5,-CONR 4 R 5和-COOR 4; 当m为2至4时,R1另外选自C1-6烷氧基,羟基,NR4R5,-NR4SO2R5,-NR4SOR5,-NR4COR5和-NR4CONR4R5; R2选自氢,C1-6烷基和 - (CH2)n-C3-7环烷基; R3为基团R6选自氢和C1-4烷基; U选自甲基和卤素; X和Y各自独立地选自氢,甲基和卤素; m选自0,1,2,3和4,其中所得碳链的每个碳原子可以任选被一个或两个独立地选自C 1-6烷基的基团取代; n选自0,1,2和3; r选自0,1和2; 或其药学上可接受的盐或溶剂化物,以及它们作为药物的用途,特别是作为p38激酶抑制剂。
摘要:
Compounds capable of providing a therapeutic effect at a target site within a human or animal body with reduced systemic potency to said body are identified by comparing the susceptibility to hydrolysis of the compound in the presence of a purified lactonase enzyme or a recombinant form of it to the corresponding susceptibility in the absence of said lactonase enzyme, and then selecting a compound on the basis of enhanced susceptibility to hydrolysis in the presence of said lactonase enzyme
摘要:
Compounds of formula (I), wherein R3 is the group; or pharmaceutically acceptable salts or solvates thereof, and their use as pharmaceuticals, particularly as p38 kinase inhibitors.